Patents by Inventor Scott Rollins
Scott Rollins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6905657Abstract: In a liquid handling system including a liquid handling substrate having a plurality of channels for conducting a liquid sample in said substrate, where the channels terminate in a plurality of exit ports in an outer surface of the substrate for transfer of a quantity of the liquid sample. The handling system also includes a liquid storage and dispensing substrate having a plurality of separable cartridges corresponding to the channels, with each cartridge terminating at a microelectro mechanical system (MEMS) comprising a laminate of glass, silicon and a piezoelectric substance. The handling system further includes a liquid detecting system comprising a light emitting diode and a photo-detector, where each channel includes a reservoir in communication with a corresponding cartridge creating an interface therebetween.Type: GrantFiled: April 5, 2001Date of Patent: June 14, 2005Assignee: BioProcessors Corp.Inventors: Allyn Hubbard, Samesh Kale, Scott Rollins, Jeremy P. Springhorn, Stephen P. Squinto, Prasad R. Akkapeddi
-
Publication number: 20050118074Abstract: In a liquid handling system including a liquid handling substrate having a plurality of channels for conducting a liquid sample in said substrate, where the channels terminate in a plurality of exit ports in an outer surface of the substrate for transfer of a quantity of the liquid sample. The handling system also includes a liquid storage and dispensing substrate having a plurality of separable cartridges corresponding to the channels, with each cartridge terminating at a microelectro mechanical system (MEMS) comprising a laminate of glass, silicon and a piezoelectric substance. The handling system further includes a liquid detecting system comprising a light emitting diode and a photo-detector, where each channel includes a reservoir in communication with a corresponding cartridge creating an interface therebetween.Type: ApplicationFiled: December 28, 2004Publication date: June 2, 2005Applicant: BioProcessors Corp.Inventors: Allyn Hubbard, Samesh Kale, Scott Rollins, Jeremy Springhorn, Stephen Squinto, Prasad Akkapeddi
-
Publication number: 20040268157Abstract: A data processing network includes a set of servers, at least one switch module to interconnect the servers, and a management module. The management module consults power state information stored in the network following a power transition and restores power to at least some of the servers and switch modules based on the power state information. The power state information prevents the management module from restoring power to servers and switch modules having incompatible communication protocols. In one embodiment, the plurality of servers and the switch modules are hot-swappable modules that are all inserted into a single chassis. In this embodiment, the server modules and at least one switch module share selected resources of the network including system power. The switch modules and servers may employ Ethernet, fibre channel, optical, and serial communication protocols.Type: ApplicationFiled: June 25, 2003Publication date: December 30, 2004Applicant: International Business Machines CorporationInventors: Gregory William Dake, Jeffrey Michael Franke, Donald Eugene Johnson, Shane Michael Lardinois, Michael Scott Rollins, David Robert Woodham
-
Publication number: 20040117536Abstract: When a blade and/or interconnect device is inserted into the chassis of a powered or live server the procedure is known as hot-plugging. Before power is applied to the hot-plugged blade and/or interconnect device the fabric type of already installed blades and/or interconnect devices is correlated with fabric types of newly hot-plugged blade and/or interconnect device. Depending upon results of the correlation, power to the hot-plugged blade and/or interconnect device is allowed or denied.Type: ApplicationFiled: November 27, 2002Publication date: June 17, 2004Applicant: International Business Machines Corporation, Armonk , New YorkInventors: Jeffery Michael Franke, Donald Eugene Johnson, Michael Scott Rollins, David Robert Woodham
-
Publication number: 20040103180Abstract: Signals to a management module are generated on an occurrence of an event affecting one of a plurality of server blades housed in a common chassis with the management module and aggregated in the management module. Signaling in accordance with this invention may be originated at a number of levels of operation of information handling systems, and distinction can be drawn between an occurrence requiring prompt attention from an operator—an alert—and occurrences where such prompt action is unnecessary. Occurrences signaled are logged for possible later review, and such a log will, in the contemplation of this invention, contain events related to a number of server blades.Type: ApplicationFiled: November 27, 2002Publication date: May 27, 2004Applicant: International Business Machines CorporationInventors: Rodney Hugh Brown, Gregory William Dake, Jeffery M. Franke, Donald Eugene Johnson, Edward Joseph Klodnicki, Carl Anthony Morrell, Chetan Dhirubhai Patel, Michael Scott Rollins, William Bradley Schwartz, David R. Woodham
-
Publication number: 20030135767Abstract: A method for co-operative thermal management of a number of independent electronic devices housed within a common enclosure that includes designating a priority number and measuring a temperature for each of the independent electronic devices. Next, for each of the independent electronic devices, the measured temperature is evaluated to determine if it exceeds a threshold value for the independent electronic device. If the measured temperature exceeds a threshold value, a count-down value is initialize to the designated priority number of the independent electronic device. Following which, the count-down value is evaluated to determine if it is equal to zero. If the count-down value is equal to zero, the independent electronic device is powered down. However, if the count-down value is not equal to zero, a specified time interval is allowed to expire before the count-down value is decremented and re-evaluated to determine if it is equal to zero.Type: ApplicationFiled: January 11, 2002Publication date: July 17, 2003Applicant: International Business Machines CorporationInventors: Simon Chu, James Edward Hughes, James Franklin Macon, William Joseph Piazza, Michael Scott Rollins, Sharon Lynn Sanders-Fore, Hoyt Conis Simmons
-
Publication number: 20020045247Abstract: Methods and compositions are provided for facilitating gene therapy procedures involving the transduction of target cells with retroviral vector particles in the presence of complement containing body fluids. The reduction of levels of galactose alpha (1,3) galactosyl epitopes on the retroviral vector particles and/or the blockade of antibody binding to such epitopes have been found to render the particles less sensitive to inactivation by complement mediated mechanisms, and to thus allow transduction in the presence of complement containing body fluids. Means are provided for obtaining such reductions.Type: ApplicationFiled: May 8, 1997Publication date: April 18, 2002Inventors: RUSSELL P. ROTHER, SCOTT A. ROLLINS, WILLIAM L. FODOR, JEREMY P. SPRINGHORN, STEPHEN P. SQUINTO
-
Patent number: 6355245Abstract: The use of anti-C5 antibodies, e.g., monoclonal antibodies, to treat glomerulonephritis (GN) is disclosed. The administration of such antibodies at low dosage levels has been found to significantly reduce glomerular inflammation/enlargement and other pathologic conditions associated with GN. Also disclosed are anti-C5 antibodies and anti-C5 antibody-encoding nucleic acid molecules. These antibodies are useful in the treatment of GN and other inflammatory conditions involving pathologic activation of the complement system.Type: GrantFiled: June 7, 1995Date of Patent: March 12, 2002Assignee: Alexion Pharmaceuticals, Inc.Inventors: Mark J. Evans, Louis A. Matis, Eileen Elliott Mueller, Steven H. Nye, Scott Rollins, Russell P. Rother, Jeremy P. Springhorn, Stephen P. Squinto, Thomas C. Thomas, James A. Wilkins
-
Publication number: 20020025582Abstract: In a liquid handling system including a liquid handling substrate having a plurality of channels for conducting a liquid sample in said substrate, where the channels terminate in a plurality of exit ports in an outer surface of the substrate for transfer of a quantity of the liquid sample. The handling system also includes a liquid storage and dispensing substrate having a plurality of separable cartridges corresponding to the channels, with each cartridge terminating at a microelectro mechanical system (MEMS) comprising a laminate of glass, silicon and a piezoelectric substance. The handling system further includes a liquid detecting system comprising a light emitting diode and a photo-detector, where each channel includes a reservoir in communication with a corresponding cartridge creating an interface therebetween.Type: ApplicationFiled: April 5, 2001Publication date: February 28, 2002Inventors: Allyn Hubbard, Samesh Kale, Scott Rollins, Jeremy P. Springhorn, Stephen P. Squinto, Prasad R. Akkapeddi
-
Patent number: 6338820Abstract: An apparatus for performing a assays includes an axially rotatable substrate including a plurality of layers of a semiconductor material and numerous radially-arrayed reaction sites. The apparatus further includes a rotary stepper motor which rotates the substrate at an adjustable and substantially continuous speed and controls the rotation of the substrate by adjusting the speed and a direction of rotation. In addition, the apparatus includes a dual function head which has a fluid dispenser that has a fluid dispenser outlet and delivers a fluid to a reaction site and also has a readout device that has a sensor which receives an identifying signal from the reaction site on the substrate or scans the substrate to read identifying marks at the reaction site. Moreover, the apparatus may be aligned by a computer having a memory for storing a start location for the dispenser outlet on the substrate and additional electronics.Type: GrantFiled: August 14, 1998Date of Patent: January 15, 2002Assignee: Alexion Pharmaceuticals, Inc.Inventors: Allyn Hubbard, Samesh Kale, Scott A. Rollins, Jeremy P. Springhorn, Stephen P. Squinto
-
Patent number: 6230480Abstract: A system and method for increasing the specific output of a combined cycle power plant and providing flexibility in the power plant rating, both without a commensurate increase in the plant heat rate, is disclosed. The present invention demonstrates that the process of upgrading thermal efficiencies of combined cycles can often be accomplished through the strategic use of additional fuel and/or heat input. In particular, gas turbines that exhaust into HRSGs, can be supplemental fired to obtain much higher steam turbine outputs and greater overall plant ratings, but without a penalty on efficiency. This system and method by in large defines a high efficiency combined cycle power plant that is predominantly a Rankine (bottoming) cycle. Exemplary embodiments of the present invention include a load driven by a topping cycle engine (TCE), powered by a topping cycle fluid (TCF) which exhausts into a heat recovery device (HRD).Type: GrantFiled: July 23, 1999Date of Patent: May 15, 2001Inventor: William Scott Rollins, III
-
Patent number: 6100443Abstract: Genetically engineered cells are provided which can serve as universal donor cells in such applications as reconstruction of vascular linings or the administration of therapeutic agents. The cells include a coding region which provides protection against complement-based lysis, i.e., hyperacute rejection. In addition, the cell's natural genome is changed so that functional proteins encoded by either the class II or both the class I and the class II major histocompatibility complex genes do not appear on the cell's surface. In this way, attack by T-cells is avoided. Optionally, the cells can include a self-destruction mechanism so that they can be removed from the host when no longer needed.Type: GrantFiled: June 7, 1995Date of Patent: August 8, 2000Assignees: Oklahoma Medical Research Foundation, Yale UniversityInventors: Peter J. Sims, Alfred L. M. Bothwell, Eileen A. Elliot, Richard A. Flavell, Joseph Madri, Scott Rollins, Leonard Bell, Stephen Squinto
-
Patent number: 6074642Abstract: The use of anti-C5 antibodies, e.g., monoclonal antibodies, to treat glomerulonephritis (GN) is disclosed. The administration of such antibodies at low dosage levels has been found to significantly reduce glomerular inflammation/enlargement and other pathologic conditions associated with GN.Type: GrantFiled: May 2, 1994Date of Patent: June 13, 2000Assignee: Alexion Pharmaceuticals, Inc.Inventors: Yi Wang, Louis Matis, Scott Rollins
-
Patent number: 6040428Abstract: A porcine E-selectin protein, its amino acid sequence, the sequence of a cDNA encoding the protein, antibodies reactive with the protein, and methods for the use of these molecules are disclosed. The molecules are used to diagnose the rejection of xenotransplanted pig organs, as well as to prevent and treat such transplant rejection.Type: GrantFiled: March 25, 1999Date of Patent: March 21, 2000Assignee: Alexion Pharmaceuticals, Inc.Inventors: Scott Rollins, Russell P. Rother, Louis A. Matis, Mark J. Evans
-
Patent number: 5891645Abstract: A porcine E-selectin protein, its amino acid sequence, the sequence of a cDNA encoding the protein, antibodies reactive with the protein, and methods for the use of these molecules are disclosed. The molecules are used to diagnose the rejection of xenotransplanted pig organs, as well as to prevent and treat such transplant rejection.Type: GrantFiled: June 1, 1994Date of Patent: April 6, 1999Assignee: Alexion Pharmaceuticals, Inc.Inventors: Scott Rollins, Russell P. Rother, Louis A. Matis, Mark J. Evans
-
Patent number: 5871997Abstract: Methods and compositions are provided for facilitating gene therapy procedures involving the transduction of target cells with retroviral vector particles in the presence of complement containing body fluids. The reduction of levels of galactose alpha (1,3) galactosyl epitopes on the retroviral vector particles and/or the blockade of antibody binding to such epitopes have been found to render the particles less sensitive to inactivation by complement mediated mechanisms, and to thus allow transduction in the presence of complement containing body fluids. Means are provided for obtaining such reductions.Type: GrantFiled: March 6, 1995Date of Patent: February 16, 1999Assignee: Alexion Pharmaceuticals, Inc.Inventors: Russell P. Rother, Scott A. Rollins, William L. Fodor, Jeremy P. Springhorn, Stephen P. Squinto
-
Patent number: 5853722Abstract: The use of anti-C5 antibodies to reduce the dysfunction of the immune and hemostatic systems associated with extracorporeal circulation procedures, such as, cardiopulmonary bypass procedures, is disclosed. The antibodies have been found to significantly reduce complement activation, platelet activation, leukocyte activation, and platelet-leukocyte adhesion associated with such procedures.Type: GrantFiled: December 21, 1995Date of Patent: December 29, 1998Assignees: Alexion Pharmaceuticals, Inc., Yale UniversityInventors: Scott Rollins, Brian R. Smith, Stephen P. Squinto
-
Patent number: 5847082Abstract: Nucleic acid sequences encoding chimeric proteins that comprise a functional portion of a parent terminal complement inhibitor, such as CD59, and a heterologous transmembrane domain are provided. The parent terminal complement inhibitor is modified to inactivate its GPI signal sequence. The heterologous transmembrane domain serves to anchor the chimeric protein to the cell membrane without substantially interfering with the complement inhibitor activity of the terminal complement inhibitor. The nucleic acid sequences and encoded chimeric proteins can be used to protect cells from complement attack.Type: GrantFiled: June 7, 1995Date of Patent: December 8, 1998Assignee: Alexion Pharmaceuticals, Inc.Inventors: Russell Rother, Scott Rollins, Stephen P. Squinto
-
Patent number: 5705732Abstract: Genetically engineered cells are provided which can serve as universal donor cells in such applications as reconstruction of vascular linings or the administration of therapeutic agents. The cells include a coding region which provides protection against complement-based lysis, i.e., hyperacute rejection. In addition, the cell's natural genome is changed so that functional proteins encoded by either the class II or both the class I and the class II major histocompatibility complex genes do not appear on the cell's surface. In this way, attack by T-cells is avoided. Optionally, the cells can include a self-destruction mechanism so that they can be removed from the host when no longer needed.Type: GrantFiled: July 1, 1993Date of Patent: January 6, 1998Assignees: Oklahoma Medical Research Foundation, Yale UniversityInventors: Peter J. Sims, Alfred L.M. Bothwell, Eileen A. Elliot, Richard A. Flavell, Joseph Madri, Scott Rollins, Leonard Bell, Stephen Squinto
-
Patent number: 5627264Abstract: Chimeric complement inhibitor proteins are provided which include a first functional domain (first amino acid sequence) having C3 inhibitory activity and a second functional domain (second amino acid sequence) having C5b-9 inhibitory activity. The first functional domain is amino terminal to the second functional domain. In this way, the chimeric protein exhibits both C3 and C5b-9 inhibitory activity. The other orientation, i.e., the orientation in which the second amino acid sequence is amino terminal to the first amino acid sequence, only produces C3 inhibitory activity. Nucleic acid molecules encoding such proteins are also provided.Type: GrantFiled: March 3, 1994Date of Patent: May 6, 1997Assignee: Alexion Pharmaceuticals, Inc.Inventors: William L. Fodor, Scott Rollins, Stephen P. Squinto